[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349568-105":59,"doc-detail-349568-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","exploring-the-clinical-transformation-of-circrna-as-a-biomarker-in-breast-cancer","Exploring the Clinical Transformation of circRNA as a Biomarker in Breast Cancer","","This narrative review systematically examines the potential of circular RNAs (circRNAs) as clinical biomarkers in breast cancer, focusing on the translational gap between basic discoveries and clinical applications. circRNAs are covalently closed non-coding RNA molecules with high stability and tissue-specific expression, making them promising candidates for liquid biopsy. In breast cancer’s heterogeneous landscape, circRNA expression profiles show subtype-specific patterns linked to tumorigenesis, progression, and therapy resistance, while EV-carried signatures enable non-invasive detection. Translation is limited by detection standardization, functional validation, and the lack of prospective large-cohort studies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-clinical-transformation-of-circrna-as-a-biomarker-in-breast-cancer/349568/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-clinical-transformation-of-circrna-as-a-biomarker-in-breast-cancer/349568.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are circRNAs considered promising clinical biomarkers for breast cancer?","Question",{"text":113,"@type":114},"circRNAs are covalently closed non-coding RNAs with high stability and tissue-specific expression, supporting detection in body fluids for liquid biopsy. Their expression also shows subtype-specific patterns in breast cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do circRNAs influence breast cancer biology?",{"text":118,"@type":114},"circRNAs can act as microRNA sponges, interact with RNA-binding proteins, and may encode functional polypeptides, affecting cancer stem cell properties, immune escape, and organ-specific metastasis.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges hinder clinical translation of circRNA biomarkers?",{"text":122,"@type":114},"Key barriers include lack of detection standardization, insufficient functional validation, and the absence of prospective large-cohort studies to confirm clinical utility.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349568,1790182633,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Exploring the Clinical Transformation ofcircRNA as a Biomarker in Breast Cancer  \nXin Ma1 , Jing Du1, and Donghai Li1  \nCancer Control Volume 33: 1–23 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748261481227](DOI: 10.1177/10732748261481227)  \n[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nAbstract  \nThis narrative review systematically examines the potential of circular RNAs (circRNAs) as clinical biomarkers in breast cancer, focusing on the translational gap between basic discoveries and clinical applications. circRNAs are covalently closed non-coding RNA molecules characterized by high stability and tissue-specific expression, making them promising candidates for liquid biopsy. In breast cancer, a highly heterogeneous disease, circRNA expression profiles exhibit subtype-specific patterns and are associated with tumorigenesis, progression, and therapeutic resistance. Mechanistically, circRNAs function as microRNA sponges, interact with RNA-binding proteins, and can even encode functional polypeptides, thereby influencing cancer stem cell properties, immune escape, and organ-specific metastasis. Tumor-derived extracellular vesicles (EVs) carry circRNA signatures that offer a novel source for non-invasive biomarker detection. However, clinical translation is hindered by challenges in detection standardization, functional validation, and a lack of prospective, large-cohort studies. This review critically evaluates the biological functions and clinical relevance of circRNAs, discusses the role of EV-derived circRNAs in metastasis monitoring, and outlines a roadmap to overcome current translational bottlenecks, ultimately assessing their potential as diagnostic, prognostic, and predictive tools in breast cancer management.  \nKeywords  \ncircular RNA, breast cancer, biomarker, liquid biopsy, extracellular vesicles, clinical translation Received: 28 May 2026; Revised: 27 July 2026; Accepted: 6 August 2026  \n1. Introduction  \nBreast cancer is one of the most common malignant tumors among women worldwide and poses a severe threat to women’s health. According to the estimated new breast cancer cases extracted from the Global Cancer Observatory (GLOBOCAN), the number of new breast cancer cases globally has reached 2.3 million, surpassing lung cancer to become the “most commonly diagnosed cancer worldwide”, and its mortality rate remains high, with the burden of breast cancer expected to continue to rise in the future, especially in transitioning countries.1 The high heterogeneity of breast cancer is reflected in its complex molecular subtypes—including luminalA, luminalB, HER2-positive, and triple-negative breast cancer (basal-like and claudin-low)—as well as its diverse clinical behaviors and markedly different treatment responses.2 Despite remarkable progress having been made in the diagnosis and treatment of early-stage breast cancer, strategies for preventing or treating metastatic disease remain inadequate, and recurrence, metastasis and therapeutic resistance are still core clinical challenges.3 Therefore, the discovery of novel biomarkers for precise diagnosis, prognosis assessment and treatment monitoring is an important direction in breast cancer research.  \n1Department of Thyroid Breast Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China  \nCorresponding author:  \nDonghai Li, Department of Thyroid Breast Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot North Street, Hohhot, Inner Mongolia 010050, China.  \nEmail: [41031510@qq.com](41031510@qq.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and dist","cbCailmUwUeXc8U6","https://ap.wps.com/l/cbCailmUwUeXc8U6","pdf",4823993,23,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Breast cancer burden and heterogeneity\n## Need for new biomarkers","[{\"question\":\"Why are circRNAs considered promising clinical biomarkers for breast cancer?\",\"answer\":\"circRNAs are covalently closed non-coding RNAs with high stability and tissue-specific expression, supporting detection in body fluids for liquid biopsy. Their expression also shows subtype-specific patterns in breast cancer.\"},{\"question\":\"How do circRNAs influence breast cancer biology?\",\"answer\":\"circRNAs can act as microRNA sponges, interact with RNA-binding proteins, and may encode functional polypeptides, affecting cancer stem cell properties, immune escape, and organ-specific metastasis.\"},{\"question\":\"What challenges hinder clinical translation of circRNA biomarkers?\",\"answer\":\"Key barriers include lack of detection standardization, insufficient functional validation, and the absence of prospective large-cohort studies to confirm clinical utility.\"}]","Exploring the Clinical Transformation of circRNA as a Biomarker in Breast Cancer | PDF",1790084338,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c264b3473c3dd429f775d4c508ea6ab.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6e8a25b0478c15988fa09ff3b2f3161.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64020919da45819063e8333ffdd5ff0f.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0817d4ae485249ca77bbc243a112a94.webp",980,1306]